vTv Therapeutics (VTVT) announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes
- Buy Rating for vTv Therapeutics: Promising Potential of Cadisegliatin in Type 1 Diabetes Treatment
- vTv Therapeutics reports Q1 EPS (77c), consensus (81c)
- vTv Therapeutics reports reinitiation of screening in CATT1 Phase 3 trial
- VTVT Upcoming Earnings Report: What to Expect?